MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), has commenced following Health Authorities' approval, the Phase 2 clinical study into the safety and efficacy of its PTL101 capsules in treating refractory epilepsy in children.
(NetworkNewsWire) Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), on February 1, 2017, named Michael R. Dougherty to its board. A biopharmaceutical company, Marinus is preparing to initiate phase 2 studies of ganaxolone, a drug which treats seizures and anxiety in patients suffering from epilepsy and neuropsychiatric disorders.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide its quarterly activities report for the period ended 31 December 2016.
MMJ PhytoTech (ASX:MMJ) is pleased to advise that Canadian-based Harvest One Capital Corp. (CVE:WON.H) has increased its private placement to C$22 million, plus an over-allotment option of up to an additional C$3 million. Under the increased offering, Harvest One may issue up to 33,333,333 subscription receipts at a price of $0.75 per Subscription Receipt.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. (NYSE:ZTS) for Detach(TM), Anatara's non-antibiotic anti-infective product.
(NetworkNewsWire) It is no secret that cancer remains a global epidemic. According to The National Cancer Institute (http://nnw.fm/45u7N), cancer is still one of the leading causes of death in the world, with more than 8.2 million cancer-related deaths back in 2012. The American Cancer Society (http://nnw.fm/2qYuX) estimates that in 2017, just in the U.S., there will be over 1.6 million new cancer cases, with more than 600,000 cancer-related deaths, and the number of new cancer cases is expected to rise to 22 million within the next 20 years.
NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.
